1. Search Result
Search Result
Isoforms Recommended: CXCR7
Results for "

CXCR7

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

1

Fluorescent Dyes

7

Peptides

1

Inhibitory Antibodies

1

Recombinant Proteins

1

Isotope-Labeled Compounds

4

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10046
    Plerixafor
    Maximum Cited Publications
    102 Publications Verification

    AMD 3100; JM3100; SID791

    CXCR HIV Infection Inflammation/Immunology Endocrinology Cancer
    Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM [7].
    Plerixafor
  • HY-142617
    ACT-1004-1239
    2 Publications Verification

    CXCR Neurological Disease Inflammation/Immunology Cancer
    ACT-1004-1239 is a potent, selective, orally active CXCR7 antagonist with an IC50 value of 3.2 nM .
    ACT-1004-1239
  • HY-139643
    CXCR7 antagonist-1
    2 Publications Verification

    CXCR Adrenergic Receptor Inflammation/Immunology Cancer
    CXCR7 antagonist-1 is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases .
    CXCR7 antagonist-1
  • HY-110318
    VUF11207 fumarate
    3 Publications Verification

    CXCR Inflammation/Immunology Cancer
    VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
    VUF11207 fumarate
  • HY-139643A
    CXCR7 antagonist-1 hydrochloride
    2 Publications Verification

    CXCR Adrenergic Receptor Inflammation/Immunology Cancer
    CXCR7 antagonist-1 hydrochloride is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 hydrochloride is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases .
    CXCR7 antagonist-1 hydrochloride
  • HY-112154

    CXCR Cardiovascular Disease Endocrinology
    CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (CXCR7), with a Ki of 13 nM.
    CXCR7 modulator 2
  • HY-P1102
    TC14012
    4 Publications Verification

    CXCR HIV Infection Cancer
    TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. TC14012 is a potent CXCR7 agonist with an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity .
    TC14012
  • HY-P1682A
    Balixafortide TFA
    1 Publications Verification

    POL6326 TFA

    CXCR Arrestin Cancer
    Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .
    Balixafortide TFA
  • HY-107987

    CXCR Endocrinology
    CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid CXCR7 modulator, with a Ki of 9 nM .
    CXCR7 modulator 1
  • HY-167851

    CXCR Neurological Disease Cancer
    CCX662 is a selective CXCR7 inhibitor with human IC50 values of 9 nM (buffer) and 18 nM (100% human serum), and rat IC50 of 14 nM (100% rat serum). CCX662 blocks CXCL12 binding to CXCR7, inhibits CXCR4-directed trans-endothelial migration of CXCR4 +/CXCR7 + cells. CCX662 can be used for the research of glioblastoma multiforme .
    CCX662
  • HY-D0976
    NF279
    1 Publications Verification

    P2X Receptor HIV NTPDase CXCR Infection
    NF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC50 value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection .
    NF279
  • HY-123813

    CXCR Arrestin Cancer
    CCX-777 is an orthosteric binder and partial agonist of CXCR7/ACKR3. CCX-777 induces the recruitment of β-arrestin 2 and affects the rebinding of chemokines to ACKR3. CCX-777 functions to stabilize the ACKR3 receptor and promotes the formation of a monodisperse, stable complex of the receptor in DDM/CHS micelles. CCX-777 is widely used in cancer-related research .
    CCX-777
  • HY-P1682
    Balixafortide
    1 Publications Verification

    POL6326

    CXCR Arrestin Cancer
    Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .
    Balixafortide
  • HY-100677
    VUF11207
    3 Publications Verification

    CXCR Endocrinology
    VUF11207 (Compound 29) is a CXCR7 agonist and a high-potency CXCR7 (pKi of 8.1) ligand that induces recruitment of β-arrestin2 (pEC50 of 8.8) and subsequent internalization (pEC50 of 7.9) of CXCR7 .
    VUF11207
  • HY-P10333A

    CXCR Neurological Disease Inflammation/Immunology
    LIH383 TFA is an agonist of ACKR3 (CXCR7) (EC50=0.61 nM). LIH383 TFA efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling .
    LIH383 TFA
  • HY-10046S

    Isotope-Labeled Compounds CXCR HIV Infection Inflammation/Immunology Endocrinology Cancer
    Plerixafor-d4 is the deuterium labeled Plerixafor. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM [7].
    Plerixafor-d4
  • HY-107987R

    Reference Standards CXCR Endocrinology
    CXCR7 modulator 1 (Standard) is the analytical standard of CXCR7 modulator 1 (HY-107987). This product is intended for research and analytical applications. CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid CXCR7 modulator, with a Ki of 9 nM .
    CXCR7 modulator 1 (Standard)
  • HY-W019787

    Opioid Receptor CXCR Neurological Disease
    BAM-12P, an endogenous opioid peptide, is a novel pro-Met-enkephalin. BAM-12P can activate human κ-opioid receptor (hKOR) with an EC50 of 101 nM and a pEC50 of 6.99. BAM-12P is a ligand for CXCR7 with an EC50 of 175 nM .
    BAM-12P
  • HY-P1102A

    CXCR HIV Infection Cancer
    TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. TC14012 TFA is a potent CXCR7 agonist with an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 TFA has anti-HIV activity and anti-cancer activity .
    TC14012 TFA
  • HY-RS00162

    Small Interfering RNA (siRNA) Others

    ACKR3 Human Pre-designed siRNA Set A contains three designed siRNAs for ACKR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ACKR3 Human Pre-designed siRNA Set A
    ACKR3 Human Pre-designed siRNA Set A
  • HY-10046R

    AMD 3100 (Standard); JM3100 (Standard); SID791 (Standard)

    Reference Standards CXCR HIV Infection Inflammation/Immunology Endocrinology Cancer
    Plerixafor (Standard) is the analytical standard of Plerixafor. This product is intended for research and analytical applications. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM [7].
    Plerixafor (Standard)
  • HY-172541

    CXCR Cardiovascular Disease
    LN6023 (hydrochloride) (Compound 27) is a CXCR7 agonist. LN6023 (hydrochloride) induces the recruitment of β-arrestin in HEK293T cells expressing human CXCR7 (EC50 = 3.5 µM). LN6023 (hydrochloride) reduces the surface level of P-selectin in isolated and washed human platelets. LN6023 (hydrochloride) can be used to study platelet-mediated thrombosis .
    LN6023 hydrochloride
  • HY-115615

    CXCR Endocrinology
    VUF11207 (Compound 29) TFA is a CXCR7 agonist (pKi of 8.1) that induces recruitment of β-arrestin2 (pEC50 of 8.8) and subsequent internalization (pEC50 of 7.9) of CXCR7 .
    VUF11207 TFA
  • HY-P10333

    CXCR Neurological Disease Inflammation/Immunology
    LIH383 is an agonist of ACKR3 (CXCR7) (EC50=0.61 nM). LIH383 efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling .
    LIH383
  • HY-RS00163

    Small Interfering RNA (siRNA) Others

    Ackr3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ackr3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ackr3 Mouse Pre-designed siRNA Set A
    Ackr3 Mouse Pre-designed siRNA Set A
  • HY-182533

    CXCR Cardiovascular Disease
    LN5972 is a selective ACKR3 agonist with an EC50 of 3.40 μM, showing higher selectivity for ACKR3 over CXCR4. LN5972 induces β-arrestin recruitment to ACKR3/CXCR7. LN5972 reduces the surface expression of P-selectin. LN5972 is applicable to studies related to platelet-mediated thrombosis .
    LN5972
  • HY-123813A

    CXCR Arrestin Cancer
    CCX-777 formic is an orthosteric binder and partial agonist of CXCR7/ACKR3. CCX-777 formic induces the recruitment of β-arrestin 2 and affects the rebinding of chemokines to ACKR3. CCX-777 formic functions to stabilize the ACKR3 receptor and promotes the formation of a monodisperse, stable complex of the receptor in DDM/CHS micelles. CCX-777 formic is widely used in cancer-related research .
    CCX-777 formic
  • HY-D2201

    Fluorescent Dye Cancer
    Fluorescent ACKR3 antagonist 1(compound 18a) is a atypical chemokine receptor 3 antagonist .
    Fluorescent ACKR3 antagonist 1
  • HY-RS00164

    Small Interfering RNA (siRNA) Others

    Ackr3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ackr3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ackr3 Rat Pre-designed siRNA Set A
    Ackr3 Rat Pre-designed siRNA Set A
  • HY-P992405

    CXCR Cancer
    MEDI-3185 is a potent CXCR4 antagonist. MEDI-3185 binds CXCR4 via CDR3H and ECL2 β-strand/β-strand interaction, blocks SDF-1 access and displaces SDF-1. MEDI-3185 can be used for the research of hematologic tumors, ovarian tumors .
    MEDI-3185

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: